NASDAQ:XRTX XORTX Therapeutics Q2 2026 Earnings Report $1.73 +0.00 (+0.06%) Closing price 03:58 PM EasternExtended Trading$1.74 +0.01 (+0.81%) As of 04:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast XORTX Therapeutics EPS ResultsActual EPS-$1.05Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AXORTX Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AXORTX Therapeutics Announcement DetailsQuarterQ2 2026Date8/15/2026TimeAfter Market ClosesConference Call DateFriday, August 14, 2026Conference Call Time10:35PM ETUpcoming EarningsXORTX Therapeutics' Q3 2026 earnings is estimated for Thursday, November 12, 2026, based on past reporting schedules, with a conference call scheduled at 6:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesEarnings HistoryCompany Profile XORTX Therapeutics Earnings HeadlinesXORTX Announces Planned FDA IND Submission for XRx-026 Gout Program Using XORLO(TM), Targeting USD$700M+ U.S. Gout Market OpportunitySeptember 19, 2026 | barrons.comXORTX Therapeutics Shares Rise 12% On IND Submission PlanSeptember 19, 2026 | rttnews.comDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in could be a costly mistake. He calls it among the most overhyped, overvalued large-cap offerings ever pushed onto everyday investors. Tilson believes a rare economic event is approaching - one with serious consequences for your portfolio this summer. He has prepared a free analysis outlining what he sees and the specific steps he recommends taking now.October 7 at 1:00 AM | Stansberry Research (Ad)XORT Targets FDA IND Filing For XRx-026 Gout Program; NDA Submission Planned Within A YearSeptember 18, 2026 | rttnews.comXORTX Announces Planned FDA IND Submission for XRx-026 Gout Program Using XORLO™, Targeting USD$700M+ U.S. Gout Market OpportunitySeptember 18, 2026 | globenewswire.comXORTX Begins Clinical, Commercial Manufacturing Of XORLO For Gout Program; Shares Surge To 31%September 11, 2026 | rttnews.comSee More XORTX Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like XORTX Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on XORTX Therapeutics and other key companies, straight to your email. Email Address About XORTX TherapeuticsXORTX Therapeutics (NASDAQ:XRTX) is a clinical-stage biotechnology company focused on developing therapies for diseases associated with abnormal uric acid metabolism and progressive kidney injury. The company’s research is centered on reducing uric acid production and addressing the role of uric acid in inflammation and renal disease. XORTX’s development programs include XRx-008 for autosomal dominant polycystic kidney disease, a genetic condition that causes cysts to form in the kidneys, as well as programs investigating xanthine oxidase inhibition in other kidney-related conditions. The company has also described development activities involving XRx-101 and XRx-225, which are intended to support additional applications of its uric acid-lowering platform. Headquartered in Calgary, Alberta, Canada, XORTX conducts its development activities through clinical research and regulatory programs in North America and other relevant jurisdictions. The company was founded by Allen Davidoff, who serves as chief executive officer and has been involved in its corporate and drug-development strategy.View XORTX Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Penguin Solutions Is Soaring as AI Memory Demand ExplodesWall Street Is Betting These 3 Beaten-Down Stocks Have More Room to RunLamb Weston’s Turnaround Is Starting to Look RealRPM International’s Dividend King Status Just Got StrongerAI Chip Demand Gives Linde a New Growth CatalystAllient’s Data Center and Defense Momentum Is Raising the StakesInvenTrust’s Sell-Off Opens a Potential Entry Point Upcoming Earnings PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
